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An antitumor drug, 3-(l-anilinoethylidene)-5-benzylpyrrolidine-2,4-dione (TN-16) inhibited the assembly 
of porcine brain microtubules in vitro. The assembly induced by taxol was also suppressed by the drug. 
However, the latter required much higher concentration of TN-16 than the former. Binding studies by 
means of the fluorometric method and the spun-column procedure indicate that the inhibition was caused 
by the reversible binding of the drug to the colchicine-sensitive site of tubulin. The affinity of TN-16 to 
tub&n was almost equal to that of nocodazole. 
Antitumor drug TN-16 Nocodazole 
1. INTRODUCTION 
TN-16 (fig. 1) is a synthetic compound which ar- 
rests mitosis of tumor cells at metaphase. The 
metaphase-arrested cells immediately divide when 
the drug is removed from the culture medium 
[1,21. 
Here I report that the drug inhibits the assembly 
of brain microtubules in vitro by binding to the 
colchicine-sensitive site of tubulin. 
2. MATERIALS AND METHODS 
2.1. Materials 
Nitrocellulose membrane filters (0.45 pm) and 
Sephadex G-50 were purchased from Sartorius and 
Pharmacia, respectively. TN-16 was obtained from 
Wako Pure Chemical, taxol from the US National 
Cancer Institute and nocodazole from Aldrich 
Chemical. These 3 drugs were dissolved in DMSO. 
[3H]GTP and [3H]colchicine were purchased from 
Abbreviations: TN-16, 3-(l-anilinoethylidene)~5-benzyl- 
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Fig.1. Structural formula of TN-16. 
Amersham, and phosphoenolpyruvate (PEP) and 
pyruvate kinase (PK) from Boehringer. 
2.2. Preparation of microtubule proteins 
Porcine brain microtubules were prepared by 
two cycles of temperature-dependent 
assembly-disassembly as in [3] with some 
modifications. To minimize contamination of free 
guanine nucleotides into the microtubule prepara- 
tion, second-cycle assembly was carried out with 
<50/cM GTP and a GTP regenerating system 
(1 mM PEP and 10 pg PK/ml). Microtubule pro- 
teins were finally dissolved in buffer A (0.1 M 
MES, pH 6.5, 1 mM EGTA and 0.5 mM 
magnesium acetate) containing 10pM GTP and 
25% (v/v) glycerol and stored at - 80°C until use. 
2.3. Assay methods for microtubule assembly 
Microtubule assembly was carried out in buffer 
A containing 10% (v/v) glycerol, 10 PM [3H]GTP, 
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1 mM PEP and 1Opg PK/ml. Time-course of the 
assembly was monitored by measurement of in- 
crease in turbidity at 350 nm [4] and its extent was 
assayed by incorporation of labeled guanine 
nucleotides into microtubules. The incorporation 
was measured by use of the nitrocellulose 
membrane-filter procedure [5]. Microtubules were 
assembled with 30 min incubation at 3O”C, follow- 
ed by addition of non-labeled GPT at 0.5-l .O mM 
final cont. After further incubation for 5 min at 
the same temperature, radioactive guanine 
nucleotides till bound to tubulin were collected on 
a nitrocellulose membrane filter. 
2.4. Measurement of drug-binding to tubulin 
Binding experiments were performed in buffer B 
(20 mM MES, pH 6.5, 5 mM magnesium acetate, 
0.4 M potassium acetate and 10% glycerol). Time- 
course of colchicine-binding was followed by in- 
crease in fluorescence intensity at 430 nm [6,7]. To 
assay extent of drug-binding, the spun-column 
procedure [8] was used. Amount of bound drug 
was determined from radioactivity recovered in the 
fraction of the tubulin-drug complex or from ab- 
sorbance of the fraction. For determination of col- 
chicine and TN-16, absorbance at 350 nm and 
3 15 nm, respectively. 
3. RESULTS 
3.1. Inhibition of microtubule assembly by TN-16 
Time-course of microtubule assembly was 
monitored by increase in turbidity at 350 nm. The 
assembly was inhibited when an anti-tumor drug, 
TN-16, was present in the medium. A 
stoichiometric amount of the drug showed >50% 
inhibition (fig.2A). 
To study requirement of the drug for inhibition, 
its effect on the extent of the assembly was assayed 
by the filtration procedure as in section 2. Under 
this condition, [3H]GTP bound to free tubulin was 
almost completely replaced by non-labeled GTP in 
the medium whereas [‘H]GDP incorporated into 
microtubules was not replaced [9, lo]. Therefore, 
radioactivity recovered on the filter reflects the 
amount of polymerized tubulin. As shown in 
fig.2B, 20 and 190 pmol tubulin were incorporated 
into microtubules when reaction mixtures contain- 
ed 2.5 PM (125 pmoV50 ~1) and 5.7 FM 
(285 pmoV50 ~1) tubulin, respectively. The critical 
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Fig.2. Effect of TN-16 on the assembly of porcine brain 
microtubules. (A) Microtubule proteins (-1.5 mg/ml) 
were incubated at 30°C with and without TN-16. At the 
time indicated, turbidity at 350 nm was measured: 
(-c-) without TN-16; (-t) with 10pM TN-16. (B) 
Microtubule proteins were finally dissolved in 504 
buffer A containing 10% (v/v) glycerol, 1OpM 
[3H]GTP, 1 mM phosphoenolpyruvate, 10 pg pyruvate 
kinase/ml and the indicated concentration of TN-16. 
After addition of 1~1 DMSO or 125 pM taxol, 
microtubules were assembled after 30 min incubation at 
30°C. The amount of tubulin polymerized was assayed 
by the filtration procedure in section 2: (u) 
285 pmol tubulin without taxol; (-A-) 125 pmol 
tubulin without taxol; (+) 125 pmol tubulin with 
2.5 pM taxol. 
concentration obtained from the above results was 
2.0 PM (-0.2 mg/ml). The value corresponds well 
with that in [4]. 
Fig.2B shows that the extent of inhibition by 
TN-16 depended on tubulin concentration. For 
50% inhibition of the assembly of 2.5 GM tubulin, 
0.4 PM TN-16 was required, while 1.7 PM TN-16 
was required when tubulin was 5.7 PM. The drug 
also inhibited assembly induced by taxol which is 
known to promote microtubule assembly [ll]. 
However, a much higher [TN-161 was required for 
inhibition. About 6pM TN-16 was required for 
50% inhibition of the taxol-induced assembly of 
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2.5 PM tubulin. This fact might suggest hat taxol- 
binding affects affinity of TN-16 to tubulin. 
3.2. Inhibition of colchicine binding to tub~lin 
by TN-16 
Formation of the tubulin-colchicine complex 
was monitored by an increase in fluorescence in- 
tensity at 430 nm. The increase in the fluorescence 
was suppressed when TN-16 was present (fig.3A). 
The drug has an absorption maximum at 315 nm. 
The absorbance of its 30 pM solution at the excita- 
tion wavelength is 0.17 and there is no overlap bet- 
ween the absorption spectrum of TN-16 and the 
fluorescence one of tubulin-colchicine complex. 
From these facts, it can be concluded that the 
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Fig.3. Effect of TN-16 on formation of the 
tubulin-colchicine complex. (A) Tubulin (10 FM) was 
dissolved in 2.5 ml ice-cold buffer B containing 20,&i 
GTP and 20 hM colchicine. After addition of 50~1 
DMSO or 1.5 mM TN-16, the solutions were incubated 
at 3W’C and the fluorescence intensity at 430 nm was 
measured at the time indicated. Excitation wavelength 
was 350 nm: (u) without TN-16; (-e--) with 30 PM 
TN-16. (B) Tubulin was incubated for 30 min at 30°C in 
buffer B containing 20 pM GTP, 15 pM (3HJcolchicine 
and the indicated concentration of TN-16 or 
nocodazoie. The amount of [3~lcolchicine bound was 
assayed by the spun-coIumn procedure [8]: (---) 
amount of [‘Hlcolchicine bound in the absence of TN-16 
and nocodazole; (-e-) with TN-16; (-o-) with 
nocodazole. 
presence of TN-16 has no significant effect on the 
fluorescence intensity under this condition. 
Therefore, the above result might be due to the 
fact that TN-16 inhibited the binding of colchicine 
to tubulin. The fact was confirmed by the direct 
measurement of the tubulin-[3H]colchicine com- 
plex formed. The complex was isolated by the 
spun-column procedure [S]. TN-16 inhibited the 
complex formation in a dose-dependent manner 
(fig.3B). The figure also shows that its ability for 
inhibition is almost the same as that of 
nocodazole. 
In the presence of TN-16, -5 min time lag was 
observed in the formation of the 
tubulin-colchicine complex (fig.3A). The time lag 
can be explained when we assume that TN-16 
rapidly binds to the colchicine-binding site of 
tubulin and the bound drug was gradually replaced 
by colchicine. The above assumption was confirm- 
ed in table 1. Binding of TN-16 was completed 
within 10 min even at 0°C and the bound drug was 
replaced by the colchicine added. Low recovery of 
bound TN-16 might be due to dissociation of the 
tubulin-TN-16 complex during gel filtration and 
the dissociation rate of the complex at 30°C is pro- 
bably faster than at 0°C 
Nocodazole is a synthetic inhibitor of 
Table 1 
Reversibility of TN-16 binding to tub&n 
Tube Additions TN-16 Colchicine- 
no. bound bound 
(nmol) (nmol) 
1 TN-16 (4 nmol) 0.44 
2 TN-16 (4 nmol) 0.32 - 
3 TN-16 (4 nmol) + 
colchicine (30 nmol) 0.08 0.88 
4 Colchicine (30 nmol) - 1.01 
Each of the 4 tubes contained 0.4 ml final vol.; buffer 
B, 20pM GTP, 1.2 nmol tub&n and 4 nmol TN-16 
(tubes l-3) or 30 nmol colchicine (tube 4). Tube 1 was 
incubated for 10 min at O*C and tube 4 for 60 min at 
30°C. Then the amount of TN-16 or colchicine bound 
was assayed by the spun-column procedure [8]. After 
incubation for 10 min at 30°C 2 pl distilled water and 
15 mM colchicine were added to 2 and 3, respectively. 
The 2 tubes were incubated for a further 60 min at 3O”C, 
then the amount of bound drugs was assayed 
275 
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microtubule assembly which reversibly and rapidly 
binds to the colchicine-sensitive site of tubulin 
[12,13]. These results indicate that both TN-16 and 
nocodazole bind to tubulin in the same manner. 
Furthermore, they have almost equal affinity to 
porcine brain tubulin. However, affinity of yeast 
tubulin to TN-16 is very different from that to 
nocodazole (not shown). Nocodazole and other 
benzimidazole carbamate derivatives inhibit 
growth and microtubule assembly of yeast [ 14,151, 
while growth of yeast, Saccharomyces cerevisiae, 
was not inhibited by TN-16 The result might 
reflect the fact that there is no structural relation- 
ship between the two drugs. 
3.3. Concluding remarks 
The results reported here can be summarized as 
follows: 
(i) TN-16 inhibited the microtubule assembly in 
vitro; 
(ii) The drug reversibly binds to the colchicine- 
binding site of tubulin. 
They indicate that the antitumor activity of 
TN-16 is due to its direct inhibition of the 
microtubule assembly process. Furthermore, the 
reversible binding explains the fact that tumor cells 
arrested at the metaphase begin to divide im- 
mediately after removal of the drug [ 1,2]. 
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